-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Reprint link: https://m.
The first domestic phase III clinical trial of the bivalent HPV vaccine (Synconin) was launched nationwide in November 2012, and 7372 healthy women aged 18-45 years (3689 in the vaccination group and 3,683 in the control group) were vaccinated and monitored
for 66 months 。 The results showed that vaccination had a protective effect of 100.
Domestic HPV vaccination
.
Photo by Xiong Qi, a reporter from the Xinhua News Agency
In the 66-month follow-up analysis, the vaccine was effective in inducing subjects to produce high and long-maintained HPV 16 and 18 neutralizing antibody and IgG antibody levels, showing good immune persistence
.
In addition, the vaccine was extremely safe, with no serious adverse events related to vaccination during the study period, nor abnormalities
in adverse pregnancy outcomes and neonatal health status associated with vaccination.
It is reported that the research was jointly completed
by 17 research teams including the National Cancer Center/Cancer Hospital of the Chinese Academy of Medical Sciences, the School of Public Health of Xiamen University, the Jiangsu Provincial Center for Disease Control and Prevention, the People's Hospital of Peking University, the Liuzhou Municipal Center for Disease Control and Prevention, and the China Institute of Food and Drug Control.
The research has been funded
by the National Natural Science Foundation of China, the National Key R&D Program, the Fujian Provincial Health Education Joint Research Program, the Fujian Provincial Natural Science Foundation, the R&D Fund of the Central University, the Innovation Unit of the Chinese Academy of Medical Sciences and the Medical and Health Science and Technology Innovation Project, and Xiamen Wantai Canghai Biotechnology Co.
, Ltd.
On August 29, the Lancet WeChat public account news, "The Lancet-Infectious Diseases" recently published the first domestic bivalent HPV vaccine phase III clinical trial of the final analysis study
.
On August 29, the Lancet WeChat public account news, "The Lancet-Infectious Diseases" recently published the first domestic bivalent HPV vaccine phase III clinical trial of the final analysis study
.
The first domestic phase III clinical trial of the bivalent HPV vaccine (Synconin) was launched nationwide in November 2012, and 7372 healthy women aged 18-45 years (3689 in the vaccination group and 3,683 in the control group) were vaccinated and monitored
for 66 months 。 The results showed that vaccination had a protective effect of 100.
Domestic HPV vaccination
.
Domestic HPV vaccination
.
In the 66-month follow-up analysis, the vaccine was effective in inducing subjects to produce high and long-maintained HPV 16 and 18 neutralizing antibody and IgG antibody levels, showing good immune persistence
.
It is reported that the research was jointly completed
by 17 research teams including the National Cancer Center/Cancer Hospital of the Chinese Academy of Medical Sciences, the School of Public Health of Xiamen University, the Jiangsu Provincial Center for Disease Control and Prevention, the People's Hospital of Peking University, the Liuzhou Municipal Center for Disease Control and Prevention, and the China Institute of Food and Drug Control.
The research has been funded
by the National Natural Science Foundation of China, the National Key R&D Program, the Fujian Provincial Health Education Joint Research Program, the Fujian Provincial Natural Science Foundation, the R&D Fund of the Central University, the Innovation Unit of the Chinese Academy of Medical Sciences and the Medical and Health Science and Technology Innovation Project, and Xiamen Wantai Canghai Biotechnology Co.
, Ltd.
It is reported that the research was jointly completed
by 17 research teams including the National Cancer Center/Cancer Hospital of the Chinese Academy of Medical Sciences, the School of Public Health of Xiamen University, the Jiangsu Provincial Center for Disease Control and Prevention, the People's Hospital of Peking University, the Liuzhou Municipal Center for Disease Control and Prevention, and the China Institute of Food and Drug Control.
The research has been funded
by the National Natural Science Foundation of China, the National Key R&D Program, the Fujian Provincial Health Education Joint Research Program, the Fujian Provincial Natural Science Foundation, the R&D Fund of the Central University, the Innovation Unit of the Chinese Academy of Medical Sciences and the Medical and Health Science and Technology Innovation Project, and Xiamen Wantai Canghai Biotechnology Co.
, Ltd.
In 2022, Eddy Pharmaceutical's "Spark of Fire" plan is in full swing
